- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Acyltransferase.
Displaying page 1 of 1.
EudraCT Number: 2017-004521-32 | Sponsor Protocol Number: D5780C00007 | Start Date*: 2018-08-22 | |||||||||||
Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC | |||||||||||||
Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction | |||||||||||||
Medical condition: ST-elevation myocardial infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005473-36 | Sponsor Protocol Number: Dezember2014Version2 | Start Date*: Information not available in EudraCT |
Sponsor Name:Universitätsklinikum Freiburg | ||
Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects | ||
Medical condition: familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005393-22 | Sponsor Protocol Number: RETIRD04 | Start Date*: 2016-11-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransfer... | ||||||||||||||||||
Medical condition: Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001517-32 | Sponsor Protocol Number: K-877-201 | Start Date*: 2013-10-02 | |||||||||||
Sponsor Name:Kowa Research Europe | |||||||||||||
Full Title: A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels | |||||||||||||
Medical condition: dyslipidemia (eg hyperlipidaemia, hypertriglyceridaemia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) NL (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002240-17 | Sponsor Protocol Number: ATR-101-301 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Millendo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome | |||||||||||||
Medical condition: endogenous Cushing’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004214-42 | Sponsor Protocol Number: RETIRD02 | Start Date*: 2012-09-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due ... | ||||||||||||||||||
Medical condition: Leber Congenital Amaurosis Retinitis pigmentosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003197-13 | Sponsor Protocol Number: ISIS484137-CS2 | Start Date*: 2017-11-24 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (ISIS-DGAT2RX, an Antisense Inhibitor of Diacylglycerol Acyltr... | ||||||||||||||||||
Medical condition: Hepatic Steatosis in type 2 diabetes (T2DM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
